GSK blood drug works same as placebo: FDA

Share this article:

GlaxoSmithKline's (GSK) experimental drug Promacta (eltrombopag) failed to significantly lower bleeding in patients with the rare blood disorder it was designed to treat, the FDA said.

An unnamed agency reviewer said in a document posted to the FDA's website that studies comparing Promacta to placebo showed some bleeding control but not enough to support the company's claims for treating chronic idiopathic thrombocytopenia purpura, an autoimmune disease that reduces blood platelets crucial for blood clotting.

“Although a trend toward reduced incidence of bleeding is observed in the eltrombopag group compared to placebo, this trend is not statistically significant and does not provide robust evidence to support the proposed labeling claim,” the FDA said.

Click here to read the full FDA advisory committee briefing document.

The document was released ahead of an agency advisory panel meeting on Friday to discuss Promacta. While the FDA will ultimately make the final approval decision, it usually follows the advice of its advisory panels.

Share this article:
You must be a registered member of MMM to post a comment.


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...